Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302366 · ClinicalTrials.gov registry record · Phase 2
A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01302366 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 20 participants.
The verdict
NCT01302366, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study proposes to determine the clinical activity of this agent in patients with asymptomatic multiple myeloma. It is believed that TBL12 will help delay the onset of active multiple myeloma, with very few-if any- side effects.
Interventions
- DRUG TBL12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302366
The ClinicalTrials.gov registry entry for NCT01302366 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TBL12 is the first listed.
NCT01302366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01302366 about?
NCT01302366 is a clinical study titled "A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma". This study proposes to determine the clinical activity of this agent in patients with asymptomatic multiple myeloma. It is believed that TBL12 will help delay the onset of active multiple myeloma, with very few-if any- side effects.
What is the current status of trial NCT01302366?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01302366?
The interventions under investigation include: TBL12 (DRUG).
Who is sponsoring clinical trial NCT01302366?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.